Search research articles
Contact Us
Filters
Showing results (31-40 of 52) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models
Jill M Spoerke, Carol O'Brien, Ling Huw, et al.
Cancer Research
|
August 19, 2017
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
Lingyan Jin, Jesse Garcia, Emily Chan, et al.
Plos One
|
May 10, 2012
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes
Jeffrey J Wallin, Jane Guan, Kyle A Edgar, et al.
Journal of the National Cancer Institute
|
March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma
Christy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Molecular Cancer Therapeutics
|
March 10, 2012
ERK inhibition overcomes acquired resistance to MEK inhibitors
Georgia Hatzivassiliou, Bonnie Liu, Carol O'Brien, et al.
Arthritis Research & Therapy
|
August 29, 2014
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Glynn Dennis, Cécile T J Holweg, Sarah K Kummerfeld, et al.
NPJ Precision Oncology
|
June 7, 2018
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types
Marie-Claire Wagle, Daniel Kirouac, Christiaan Klijn, et al.
Cancer Discovery
|
May 16, 2012
PPM1H is a p27 phosphatase implicated in trastuzumab resistance
Si Tuen Lee-Hoeflich, Thinh Q Pham, Don Dowbenko, et al.
Plos One
|
October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John Moffat, Gabriele Schaefer, et al.
Cancer Cell
|
March 12, 2015
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma
Hayley J Sharpe, Gregoire Pau, Gerrit J Dijkgraaf, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 52) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models
Jill M Spoerke, Carol O'Brien, Ling Huw, et al.
Cancer Research
|
August 19, 2017
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
Lingyan Jin, Jesse Garcia, Emily Chan, et al.
Plos One
|
May 10, 2012
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes
Jeffrey J Wallin, Jane Guan, Kyle A Edgar, et al.
Journal of the National Cancer Institute
|
March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma
Christy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Molecular Cancer Therapeutics
|
March 10, 2012
ERK inhibition overcomes acquired resistance to MEK inhibitors
Georgia Hatzivassiliou, Bonnie Liu, Carol O'Brien, et al.
Arthritis Research & Therapy
|
August 29, 2014
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Glynn Dennis, Cécile T J Holweg, Sarah K Kummerfeld, et al.
NPJ Precision Oncology
|
June 7, 2018
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types
Marie-Claire Wagle, Daniel Kirouac, Christiaan Klijn, et al.
Cancer Discovery
|
May 16, 2012
PPM1H is a p27 phosphatase implicated in trastuzumab resistance
Si Tuen Lee-Hoeflich, Thinh Q Pham, Don Dowbenko, et al.
Plos One
|
October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John Moffat, Gabriele Schaefer, et al.
Cancer Cell
|
March 12, 2015
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma
Hayley J Sharpe, Gregoire Pau, Gerrit J Dijkgraaf, et al.
Page
of 6